Mylan Settles With Roche For Xeloda
Mylan Inc. (NYSE:MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and [...]
Mylan Inc. (NYSE:MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and colorectal cancers. Xeloda generated revenue of $570 million in the trailing twelve months ending June 30, 2011, according to IMS Health.
The details of the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards